Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1–3% fail to reach a sustained virological response 12 weeks after end of treatment. DAA failures are characterized by advanced liver disease, specific genotypes/subtypes and resistance associated substitutions to the DAA class they have been treated with. Current European Association for the Study of the Liver guidelines recommend three therapeutic options for such patients. The first is a 12 week course of sofosbuvir (SOF), velpatasvir (VEL) and voxilaprevir (VOX), which has shown to be effective in 90–99% of patients and was granted A1 level recommendation. The second option, reserved for patients who have predictors of failure consists in 12 weeks regimen with glecaprevir (GLE) and pibrentasvir (PIB), effective in 90–97%. Finally, although not supported by published data, for especially difficult to treat patients there should theoretically be a benefit in prolonged combinations of SOF+GLE/PIB or SOF/VEL/VOX±ribavirin. This review presents the latest evidence from both clinical trials and real-life on such therapeutic strategies.
Abstract
Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1–3% fail to reach a sustained virological response 12 weeks after end of treatment. DAA failures are characterized by advanced liver disease, specific genotypes/subtypes and resistance associated substitutions to the DAA class they have been treated with. Current European Association for the Study of the Liver guidelines recommend three therapeutic options for such patients. The first is a 12 week course of sofosbuvir (SOF), velpatasvir (VEL) and voxilaprevir (VOX), which has shown to be effective in 90–99% of patients and was granted A1 level recommendation. The second option, reserved for patients who have predictors of failure consists in 12 weeks regimen with glecaprevir (GLE) and pibrentasvir (PIB), effective in 90–97%. Finally, although not supported by published data, for especially difficult to treat patients there should theoretically be a benefit in prolonged combinations of SOF+GLE/PIB or SOF/VEL/VOX±ribavirin. This review presents the latest evidence from both clinical trials and real-life on such therapeutic strategies.
참고문헌 (21)
- Aghemo A, "New horizons in hepatitis C antiviral therapy with direct-acting antivirals", Hepatology, 58, pp.428~438 (2013)
- Pawlotsky JM, "Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens", Gastroenterology, 151, pp.70~86 (2016)
- D’Ambrosio R, "Direct-acting antivirals : the endgame for hepatitis C", Curr Opin Virol, 24, pp.31~37 (2017)
- D’Ambrosio R, "Real-world effectiveness and safety of glecaprevir", pibrentasvir in 723 patients with chronic hepatitis C, 2019, pp.70, 379~387
- Mettikanont P, "Systematic review : epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection", Aliment Pharmacol Ther, 49, pp.492~505 (2019)
- Fourati S, "Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r", Hepatology, 69, pp.513~523 (2019)
- Jeong Y, "Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures", J Viral Hepat, 25, pp.1251~1259 (2018)
- Aghemo A, "What do clinicians need to watch for with direct‐acting antiviral therapy?", J Int AIDS Soc, 21(Suppl 2), pp.e25076~ (2018)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
- AASLD-IDSA HCV Guidance Panel, "Hepatitis C guidance 2018 update : AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection", Clin Infect Dis, 67, pp.1477~1492 (2018)
- Younossi ZM, "Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis : an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial", Lancet Gastroenterol Hepatol, 1, pp.122~132 (2016)
- Takehara T, "Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis : an open-label phase 3 trial", J Gastroenterol, 54, pp.87~95 (2019)
- Bourlière M, "Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection", N Engl J Med, 376, pp.2134~2146 (2017)
- "Hepatology", 2018, 418~, A-419A.
- "Hepatology", 2018, 419~, A.
- Belperio P, "Real-world effectiveness of sofosbuvir", velpatasvir, Hepatology, pp.2018, 68(Suppl 1)[DOI]
- Poordad F, "Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment", Hepatology, 66, pp.389~397 (2017)
- "Hepatology", 2018, 141~, A-142A.
- Smolders EJ, "Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and", or renal impairment, 2016, pp.39, 589~611
- Petta S, "Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis(ABACUS) : a prospective observational study", Lancet Gastroenterol Hepatol, 2, pp.427~434 (2017)
- Gane EJ, "Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen", Hepatology, 66, pp.1083~1089 (2017)